LMAT logo

LeMaitre Vascular Inc. (LMAT)

$76.10

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on LMAT

Market cap

$1.74B

EPS

2.76

P/E ratio

27.9

Price to sales

7.03

Dividend yield

1.314%

Beta

0.505344

Price on LMAT

Previous close

$77.01

Today's open

$76.83

Day's range

$75.67 - $77.53

52 week range

$75.67 - $118.01

Profile about LMAT

CEO

George W. LeMaitre

Employees

655

Headquarters

Burlington, MA

Exchange

NASDAQ Global Market

Shares outstanding

22880871

Issue type

Common Stock

LMAT industries and sectors

Healthcare

Medical Equipment & Supplies

News on LMAT

Dividend Champion, Contender, And Challenger Highlights: Week Of November 15

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

news source

Seeking Alpha • Nov 13, 2026

news preview

LeMaitre Vascular, Inc. (LMAT) Q3 2026 Earnings Call Transcript

LeMaitre Vascular, Inc. ( LMAT ) Q3 2026 Earnings Call November 4, 2026 5:00 PM EST Company Participants Dorian LeBlanc - Chief Financial Officer George LeMaitre - Chairman & CEO Conference Call Participants Michael Petusky - Barrington Research Associates, Inc., Research Division Nathan Treybeck - Wells Fargo Securities, LLC, Research Division Brett Fishbin - KeyBanc Capital Markets Inc., Research Division Daniel Stauder - Citizens JMP Securities, LLC, Research Division James Sidoti - Sidoti & Company, LLC Michael Sarcone - Jefferies LLC, Research Division Presentation Operator Welcome to the LeMaitre Vascular Q3 2026 financial results conference call. As a reminder, today's call is being recorded.

news source

Seeking Alpha • Nov 7, 2026

news preview

LeMaitre to Participate in Upcoming Investor Conferences

BURLINGTON, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences.

news source

GlobeNewsWire • Nov 6, 2026

news preview

LeMaitre Vascular Q3 Earnings Call Highlights

LeMaitre Vascular NASDAQ: LMAT reported 12% organic sales growth in the third quarter of 2026, driven by higher prices and unit volumes, while reiterating its full-year organic growth outlook and lowering its gross margin forecast.

news source

MarketBeat • Nov 5, 2026

news preview

LeMaitre Q3 2026 Financial Results

BURLINGTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q3 2026 results, announced a quarterly dividend of $0.25/share, and provided guidance.

news source

GlobeNewsWire • Nov 4, 2026

news preview

LeMaitre Vascular (LMAT) Misses Q3 Earnings Estimates

LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.65 per share, missing the Zacks Consensus Estimate of $0.69 per share. This compares to earnings of $0.62 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Dividend Income Report: +15.25% And A Listener's Portfolio Roast

This month I tried something different on the podcast - a listener sent me one of his portfolios and asked me to roast it. He holds 29 stocks with roughly equal weight, so I built a mock $100,000 portfolio and reviewed it the way I review my own money. The current portfolio yield is 1.78%, with a 5-year dividend growth CAGR of 11.69%.

news source

Seeking Alpha • Oct 31, 2026

news preview

LeMaitre Will Announce Third Quarter 2026 Earnings Results on November 4, 2026

BURLINGTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2026 financial results on Wednesday, November 4, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook.

news source

GlobeNewsWire • Oct 12, 2026

news preview

LeMaitre Vascular: The Q2 Miss Hides A Stronger Acquisition Machine

LeMaitre Vascular is rated a "Strong Buy" due to its robust M&A-driven business model, high margins, and recent valuation compression. LMAT's strategic shift to larger, higher-multiple acquisitions has improved its success rate to 80% and driven margin expansion, with gross margin rising from 65% to 72%. The company's healthy balance sheet, $376M in cash/short-term investments, and experienced management underpin its ability to pursue disciplined, accretive deals.

news source

Seeking Alpha • Oct 1, 2026

news preview

LeMaitre Vascular Data Breach Investigation: Edelson Lechtzin LLP Probes Class Action Claims After Customer Data Is Exposed

National class action law firm offers free, confidential case evaluations to LeMaitre Vascular investors, tenants, partners, and others whose personal information may have been exposed in the reported data breach. NEWTOWN, Pa.

news source

PRNewsWire • Sep 24, 2026

news preview

¹ Disclosures

Get started with M1

Invest in LeMaitre Vascular Inc.

Open an M1 investment account to buy and sell LeMaitre Vascular Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in LMAT on M1